Cure My Disease

Don't miss your cure!

 Log in / Sign up

New prostate cancer Drug's body chemistry put to the test

NCT ID NCT07548606

Completed Knowledge-focused Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed phase 1 study in 14 healthy men looked at how the experimental prostate cancer drug opevesostat behaves in the body when taken with or without another drug called itraconazole. The goal was to measure drug levels and safety, not to treat cancer. Results will help guide dosing in future trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
opevesostat (also called MK-5684 or ODM-208)
What this could lead to
If successful, this study will help determine the right dose of opevesostat for future prostate cancer trials, potentially making treatment safer and more effective.
What could go wrong
This is a very early, small study in 14 healthy men, not patients. It only measures drug levels, not whether opevesostat works against cancer. Results may not predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

  • Celerion, Inc. ( Site 0001)

    Lincoln, Nebraska, 68502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.